On the other hand, our study did not confirm a beneficial effect of lowering the markers of endothelial dysfunction (serum ADMA), systemic inflammation (high sensitivity-CRP) and vascular stiffness (ABI) after eight weeks of febuxostat treatments among patients with CKD stages III to IV patients. Here, CRP is linked to chronic kidney disease.